ENSYSCE BIOSCIENCES INC

Ensysce Biosciences boosts its pain‑therapy pipeline with the acquisition of CY200 and secures new funding, while advancing its FDA‑designated opioid‑abuse deterrent PF614‑MPAR.

Ensysce Biosciences launches final Phase‑3 trial of its MPAR opioid safety platform, a breakthrough design that limits overdose risk while preserving pain relief.